Product Name: Plk1 (37-55)
Product Number: PE-01BEZ85
Size: 200 µg      Price:48.00
1 mg      $US96.00
5 mg      208.00
Peptide Name: Plk1 (37-55)

Product Use: Services as a blocking peptide for use with the Plk1-BKCD rabbit polyclonal antibody (Cat. No.: AB-NK145-2) that is also available from Kinexus. The peptide sequence is located just before the kinase catalytic domain.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CAKEIPEVLVDPRSRRRYVR

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 2441.8 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Plk1 pan-specific antibody (Cat. No.: AB-NK145-2)

Scientific Background: Plk1 is a protein-serine/threonine kinase of the Other group and Plk family. This kinase shows high variability in human tissue distribution with the highest levels detected in colon, kidney, pancreas and testes, and is notably absent in brain and spinal cord. Plk1 is activated by phosphorylation at S49, S137, T210, and S326. It has essential roles throughout the M phase of the cell cycle, including the regulation of spindle assembly and centrosome maturation, removal of cohesins from chromosome arms, inactivation of anaphase promoting complex (APC) inhibitors, and regulation of the end of mitosis and cytokinesis. Plk1 localizes to centrosomes or spindle pole bodies and undergo dramatic subcellular relocation during the cell cycle. Deregulated activities of Plk's often result in abnormalities in centrosome duplication, maturation, and/or microtubule dynamics. Plk's also regulate the function of the Golgi complex. Plk1 might be a tumour requiring protein (TRP). Loss-of-function mutations in Plk1 result in aberrant chromosome segregation during M phase and defects in cytokinesis, leading to chromosomal defects such as polyploidy. Significantly elevated Plk1 expression has been reported in many cancer types, and Plk1 has been suggested as a potential diagnostic biomarker for several tumours. Deregulated expression of human Plk1 is strongly correlated with the development of colon and prostate cancers and lung squamous cell carcinomas (LSCC). It has been significantly associated with certain clinicopathologic indices in gallbladder carcinomas. High level expression of Plk1 was significantly associated with shorter overall survival times in gallbladder carcinomas, pericarcinomas and normal tissues (PubMEd: 23359173).